Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Harvoni

Chemical Nameledipasvir/sofosbuvir
Dosage FormTablet (oral; ledipasvir/sofosbuvir (90mg/400mg, 45mg/ 200mg)); Pellets (oral; ledipasvir/sofosbuvir (45mg/200mg, 33.75mg/150mg))
Drug ClassInhibitors
SystemBlood
CompanyGilead Sciences
Approval Year2014

Indication

  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin.
  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1 or 4 infection who are liver transplant recipients without
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Harvoni (ledipasvir and sofosbuvir) Prescribing Information.2020Gilead Sciences, Inc., Foster City, CA
Document TitleYearSource
Assessment report: Harvoni.2020EMA
Document TitleYearSource
Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis.2021Virology Journal
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.2019Journal of Hepatology
Systematic review with meta-analysis: Efficacy and safety of direct-acting antivirals for chronic hepatitis C genotypes 5 and 6.2019Biomed Research International
Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.2018Aliment Pharmacology and Therapeutics
Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: a meta-analysis.2017International Journal of Infectious Diseases